keyword
MENU ▼
Read by QxMD icon Read
search

phase III carcinoma

keyword
https://www.readbyqxmd.com/read/27913776/necitumumab-for-the-treatment-of-squamous-cell-non-small-cell-lung-cancer
#1
Jessica K Brinkmeyer, Donald C Moore
Non-small cell lung cancer is the most common form of lung cancer, accounting for about 85% of all cases and is further subdivided into adenocarcinoma, squamous cell, and large cell carcinoma. Necitumumab (Portrazza™, Eli Lilly and Company) is an anti-epidermal growth factor receptor monoclonal antibody approved for the first-line treatment of squamous cell non-small cell lung cancer in combination with cisplatin and gemcitabine. The safety and efficacy of necitumumab has been evaluated in two-phase III clinical trials, one demonstrating a lack of efficacy in non-squamous non-small cell lung cancer and another demonstrating improvement in overall survival and progression-free survival in squamous cell non-small cell lung cancer...
December 2, 2016: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/27906472/long-term-clinical-impact-and-cost-effectiveness-of-obeticholic-acid-for-the-treatment-of-primary-biliary-cholangitis
#2
Sumeyye Samur, Matthew Klebanoff, Reiner Banken, Daniel S Pratt, Rick Chapman, Daniel A Ollendorf, Anne M Loos, Kathleen Corey, Chin Hur, Jagpreet Chhatwal
: Primary biliary cholangitis (PBC) is a chronic, progressive autoimmune liver disease that mainly affects middle-aged women. Obeticholic acid (OCA), which was recently approved by the Food and Drug Administration for PBC treatment, has demonstrated positive effects on biochemical markers of liver function. Our objective was to evaluate the long-term clinical impact and cost-effectiveness of OCA as a second-line treatment for PBC in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA...
November 7, 2016: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/27904651/sunitinib-in-the-treatment-of-metastatic-renal-cell-carcinoma
#3
REVIEW
Thomas A Schmid, Martin E Gore
Sunitinib is an oral multi-targeted tyrosine kinase inhibitor (TKI) that targets various receptors, including vascular endothelial growth factor receptors (VEGFRs). Sunitinib received approval in 2006 and became a standard treatment option in the first-line treatment of metastatic renal cell cancer (mRCC) after a phase III trial showed superiority compared with interferon alpha (IFN-α). Sunitinib has also shown activity in second-line treatment in several trials. Most of the combination trials with sunitinib with various agents have led to considerable toxicity without improving efficacy...
December 2016: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/27896822/simeprevir-in-combination-with-sofosbuvir-in-treatment-na%C3%A3-ve-and-experienced-patients-with-hepatitis-c-virus-genotype-4-infection-a-phase-iii-open-label-single-arm-study-pluto
#4
M Buti, J L Calleja, S Lens, M Diago, E Ortega, J Crespo, R Planas, M Romero-Gómez, F G Rodríguez, J M Pascasio, B Fevery, D Kurland, C Corbett, R Kalmeijer, W Jessner
BACKGROUND: Hepatitis C virus (HCV) infection is a leading cause of liver cirrhosis and subsequent hepatocellular carcinoma. HCV genotype 4 is found widely in the Middle East, Egypt and Africa, and has also spread into Europe. There are limited data available regarding the use of direct-acting antiviral agents in HCV genotype 4-infected patients with cirrhosis. AIM: The Phase III, open-label, single-arm PLUTO study evaluated the efficacy and safety of 12 weeks of simeprevir (HCV NS3/4A protease inhibitor) plus sofosbuvir (HCV nucleotide-analogue NS5B polymerase inhibitor) in treatment-naïve and (peg)interferon ± ribavirin-experienced HCV genotype 4-infected patients, with or without compensated cirrhosis...
November 29, 2016: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27896243/profile-of-tivantinib-and-its-potential-in-the-treatment-of-hepatocellular-carcinoma-the-evidence-to-date
#5
REVIEW
Daniel Pievsky, Nikolaos Pyrsopoulos
Hepatocellular carcinoma (HCC) is the fastest rising cause of cancer-related death in the United States and carries a very poor prognosis, with a median survival time of <50% at 1 year for advanced disease. To date, sorafenib is the only therapy approved by the Food and Drug Administration for the treatment of advanced HCC. Tivantinib (ARQ-197), a non-ATP competitive inhibitor of cellular mesenchymal-epithelial transcription factor (c-MET), has shown a survival benefit in patients with advanced HCC who have failed or are intolerant to sorafenib in Phase I and II trials...
2016: Journal of Hepatocellular Carcinoma
https://www.readbyqxmd.com/read/27892773/real-world-data-on-nivolumab-treatment-of-non-small-cell-lung-cancer
#6
O T Brustugun, M Sprauten, Å Helland
BACKGROUND: Checkpoint inhibitors have proven effectiveness in clinical trials for non-small cell lung cancer (NSCLC) patients, but if this is congruent with routine patient care is discussed. We present real-world experience with the PD1-inhibitor nivolumab in NSCLC. PATIENTS AND METHODS: Patients with NSCLC were considered eligible for nivolumab treatment after one or more lines of chemotherapy, and when in reasonable performance status (PS) [Eastern Cooperative Oncology Group (ECOG) < 3]...
November 28, 2016: Acta Oncologica
https://www.readbyqxmd.com/read/27890494/neuroendocrine-tumors-of-the-lung-current-challenges-and-advances-in-the-diagnosis-and-management-of-well-differentiated-disease
#7
REVIEW
Andrew E Hendifar, Alberto M Marchevsky, Richard Tuli
Neuroendocrine tumors (NET) comprise a heterogeneous group of malignancies that arise from neuroendocrine cells throughout the body, most commonly originating from the lungs and gastrointestinal tract. Lung NET can be classified as well-differentiated (low-grade typical carcinoids [TC] and intermediate-grade atypical carcinoids [AC]) and poorly differentiated (high-grade large cell neuroendocrine carcinoma or small cell lung carcinoma). The incidence of these tumors is increasing, but disease awareness remains low among thoracic specialists who are often involved in the diagnosis and early treatment for these patients...
November 23, 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27889038/treatment-of-the-primary-tumor-in-anal-canal-cancers
#8
REVIEW
Rob Glynne-Jones, Sheela Rao
Radical concurrent chemoradiotherapy with 5-fluorouracil and mitomycin C (MMC) remains the standard of care for squamous cell carcinoma of the anus. Phase III trials over 2 decades have used combined radiation doses of 50 to 60 Gy with concurrent fluoropyrimidines, MMC, or cisplatin in various doses and schedules. Modern radiotherapy techniques allow the production of highly conformal plans, decreasing radiation doses to the organs at risk and ensuring a shorter overall treatment time without the need for treatment breaks...
January 2017: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/27882470/comparison-of-detrusor-muscle-sampling-rate-in-monopolar-and-bipolar-transurethral-resection-of-bladder-tumor-a-randomized-trial
#9
Jeremy Yuen-Chun Teoh, Eddie Shu-Yin Chan, Siu-Ying Yip, Ho-Man Tam, Peter Ka-Fung Chiu, Chi-Hang Yee, Hon-Ming Wong, Chi-Kwok Chan, Simon See-Ming Hou, Chi-Fai Ng
PURPOSE: Our aim was to investigate the detrusor muscle sampling rate after monopolar versus bipolar transurethral resection of bladder tumor (TURBT). METHODS: This was a single-center, prospective, randomized, phase III trial on monopolar versus bipolar TURBT. Baseline patient characteristics, disease characteristics and perioperative outcomes were compared, with the primary outcome being the detrusor muscle sampling rate in the TURBT specimen. Multivariate logistic regression analyses on detrusor muscle sampling were performed...
November 23, 2016: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/27879974/nivolumab-dose-selection-challenges-opportunities-and-lessons-learned-for-cancer-immunotherapy
#10
Shruti Agrawal, Yan Feng, Amit Roy, Georgia Kollia, Brian Lestini
BACKGROUND: Immuno-oncology (I-O) therapies target the host immune system, providing the potential to choose a uniform dose and schedule across tumor types. However, dose selection for I-O agents usually occurs early in clinical development and is typically based on tumor response, which may not fully represent the potential for improved overall survival. Here, we describe an integrated approach which incorporates clinical safety and efficacy data with data obtained from analyses of dose-/exposure-response (D-R/E-R) relationships, used to select a monotherapy dose for nivolumab, a programmed death-1 inhibitor, in clinical studies of different tumor types...
2016: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/27877008/detection-of-alk-translocation-in-non-small-cell-lung-carcinoma-nsclc-and-its-clinicopathological-significance-using-the-ventana-immunohistochemical-staining-method-a-single-center-large-scale-investigation-of-1-504-chinese-han-patients
#11
Lin Yang, Yun Ling, Lei Guo, Di Ma, Xuemin Xue, Bingning Wang, Junling Li, Jianming Ying
OBJECTIVE: The novel fully automated immunohistochemistry (IHC) assay-Ventana anaplastic lymphoma kinase (ALK)-D5F3 for screening ALK rearrangements has been approved by China's Food and Drug Administration in 2013, our previous study disclosed a highly specificity and sensitivity nearly 100%, and its efficacy needs to be evaluated in a large cohort of primary lung adenocarcinoma patients, and to compare clinicopathological features with ALK (+) and ALK (-) lung adenocarcinoma. METHODS: A total of 1,504 consecutive surgical lung adenocarcinoma cases of Chinese Han population were collected and re-diagnosed according to the 2011 multidisciplinary classification of lung adenocarcinoma...
October 2016: Chinese Journal of Cancer Research, Chung-kuo Yen Cheng Yen Chiu
https://www.readbyqxmd.com/read/27846913/induction-chemotherapy-for-locoregionally-advanced-nasopharyngeal-carcinoma
#12
Wen-Fei Li, Lei Chen, Ying Sun, Jun Ma
The value of adding induction chemotherapy (IC) to concurrent chemoradiotherapy (CCRT) for the treatment of locoregionally advanced nasopharyngeal carcinoma (NPC) remains unclear. In our recent article entitled "Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial" published in the Lancet Oncology, we reported the results of a phase III, multicenter, randomized controlled trial comparing cisplatin, 5-fluorouracil, and docetaxel (TPF) IC plus CCRT versus CCRT alone in patients with T3-4N1/TxN2-3M0 NPC (ClinicalTrials...
November 15, 2016: Chinese Journal of Cancer
https://www.readbyqxmd.com/read/27843579/a-prospective-clinical-trial-to-assess-lapatinib-effects-on-cutaneous-squamous-cell-carcinoma-and-actinic-keratosis
#13
D Jenni, M B Karpova, B Mühleisen, J Mangana, J Dreier, J Hafner, R Dummer
BACKGROUND: Antiepidermal growth factor receptor (EGFR)-targeted therapy is widely used in many epithelial cancer types. We investigated lapatinib effects on cutaneous squamous cell carcinoma (cSCC) scheduled for resection and in coexisting precursor lesions (actinic keratosis (AK) and Bowen's disease (BD)) in a phase 2 mode of action clinical trial including a histological workup of the cSCC. PATIENTS AND METHODS: We initiated a prospective single-centre, open-label, non-controlled clinical study with translational intentions to investigate changes in size and histopathological features in cSCC after a 14-day period of neoadjuvant lapatinib therapy at a dose of 1500 mg/day prior to surgery, to quantify the impact on AK and BD in the same patient after 56 days and to evaluate the tolerability in patients with cSCC and precursor lesions...
2016: ESMO Open
https://www.readbyqxmd.com/read/27821083/single-administration-of-selective-internal-radiation-therapy-versus-continuous-treatment-with-sorafenib-in-locally-advanced-hepatocellular-carcinoma-sirvenib-study-protocol-for-a-phase-iii-randomized-controlled-trial
#14
Mihir Gandhi, Su Pin Choo, Choon Hua Thng, Say Beng Tan, Albert Su Chong Low, Peng Chung Cheow, Anthony Soon Whatt Goh, Kiang Hiong Tay, Richard Hoau Gong Lo, Brian Kim Poh Goh, Jen San Wong, David Chee Eng Ng, Khee Chee Soo, Wei Ming Liew, Pierce K H Chow
BACKGROUND: Approximately 20 % of hepatocellular carcinoma (HCC) patients diagnosed in the early stages may benefit from potentially curative ablative therapies such as surgical resection, transplantation or radiofrequency ablation. For patients not eligible for such options, prognosis is poor. Sorafenib and Selective Internal Radiation Therapy (SIRT) are clinically proven treatment options in patients with unresectable HCC, and this study aims to assess overall survival following either SIRT or Sorafenib therapy for locally advanced HCC patients...
November 7, 2016: BMC Cancer
https://www.readbyqxmd.com/read/27814472/phase-iii-randomised-chemoprevention-study-with-selenium-on-the-recurrence-of-non-invasive-urothelial-carcinoma-the-selenium-and-bladder-cancer-trial
#15
Maria E Goossens, Maurice P Zeegers, Hendrik van Poppel, Steven Joniau, Koen Ackaert, Filip Ameye, Ignace Billiet, Johan Braeckman, Alex Breugelmans, Jochen Darras, Kurt Dilen, Lieven Goeman, Bertrand Tombal, Siska Van Bruwaene, Ben Van Cleyenbreugel, Frank Van der Aa, Kris Vekemans, Frank Buntinx
BACKGROUND: In Belgium, bladder cancer (BC) is the fifth most common cancer in men. The per-patient lifetime cost is high. Previous epidemiological studies have consistently reported that selenium concentrations were inversely associated with the risk of BC. We therefore hypothesised that selenium may be suitable for chemoprevention of recurrence of BC. METHOD: The Selenium and Bladder Cancer Trial (SELEBLAT) was an academic phase III placebo-controlled, double-blind, randomised clinical trial designed to determine the effect of selenium on recurrence of non-invasive urothelial carcinoma conducted in 14 Belgian hospitals...
October 28, 2016: European Journal of Cancer
https://www.readbyqxmd.com/read/27771969/vinflunine-for-the-treatment-of-non-small-cell-lung-cancer
#16
C Genova, A Alama, S Coco, E Rijavec, M G Dal Bello, I Vanni, F Biello, G Barletta, G Rossi, F Grossi
Vinflunine belongs to the class of vinca alkaloids and acts by disrupting the microtubule dynamics during cell cycle; this agent is currently available for previously treated advanced transitional cell carcinoma in Europe. The aim of this invited review is to evaluate the potential role of vinflunine for the treatment of non-small cell lung cancer (NSCLC). Areas covered: The potential role of vinflunine in NSCLC is discussed on the basis of the available data, including full papers and meeting abstracts. Relevant preclinical studies describing the pharmacological properties of vinflunine are also included...
November 1, 2016: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/27769054/biopsy-proportion-of-tumour-predicts-pathological-tumour-response-and-benefit-from-chemotherapy-in-resectable-oesophageal-carcinoma-results-from-the-uk-mrc-oe02-trial
#17
Matthew D Hale, Matthew Nankivell, Gordon G Hutchins, Sally P Stenning, Ruth E Langley, Wolfram Mueller, Nicholas P West, Alexander I Wright, Darren Treanor, Lindsay C Hewitt, William H Allum, David Cunningham, Jeremy D Hayden, Heike I Grabsch
BACKGROUND: Neoadjuvant chemotherapy followed by surgery is the standard of care for UK patients with locally advanced resectable oesophageal carcinoma (OeC). However, not all patients benefit from multimodal treatment and there is a clinical need for biomarkers which can identify chemotherapy responders. This study investigated whether the proportion of tumour cells per tumour area (PoT) measured in the pre-treatment biopsy predicts chemotherapy benefit for OeC patients. PATIENTS AND METHODS: PoT was quantified using digitized haematoxylin/eosin stained pre-treatment biopsy slides from 281 OeC patients from the UK MRC OE02 trial (141 treated by surgery alone (S); 140 treated by 5-fluorouracil/cisplatin followed by surgery (CS))...
October 18, 2016: Oncotarget
https://www.readbyqxmd.com/read/27761555/erlotinib-for-advanced-hepatocellular-carcinoma-a-systematic-review-of-phase-ii-iii-clinical-trials
#18
Jing Zhang, Yuan Zong, Gang-Zhu Xu, Ke Xing
OBJECTIVES: To evaluate the efficacy and safety of erlotinib for the treatment of advanced hepatocellular carcinoma (HCC). METHODS: A systematic literature search was undertaken in June 2015. Phase II/III trials of erlotinib for the treatment of advanced HCC were included. A descriptive analysis was applied. The study was conducted in College of Medicine, Honghui Hospital, Xi'an Jiaotong University, Xi'an, China, between June 2015 and January 2016. RESULTS: Ten trials, comprising 9 phase II and one phase III trial, were included in the systematic review...
November 2016: Saudi Medical Journal
https://www.readbyqxmd.com/read/27760933/-neoadjuvant-therapy-in-multimodal-surgical-treatment-for-squamous-cell-carcinoma-of-the-esophagus
#19
Hiroyuki Daiko, Takeo Fujita, Takashi Kojima
Postoperative chemotherapy was initially conducted with surgical treatment as part of a multimodal treatment strategy for esophageal squamous cell carcinoma. Subsequently, a randomized trial comparing post- versus pre-operative chemotherapy with cisplatin and 5-fluorouracil demonstrated the superior efficacy of neoadjuvant treatment with FP(CF). However, the results of subgroup analysis based on T factor revealed no efficacy for cT3 tumors. To improve the survival rate in patients with cT3 tumors, treatments with neoadjuvant chemotherapy using FP(CF)plus docetaxel and concurrent FP(CF)plus radiation were conducted to assess the feasibility of preoperative adjuvant treatment and surgery after neoadjuvant treatment...
October 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/27746013/cytokine-induced-killer-cell-infusion-combined-with-conventional-treatments-produced-better-prognosis-for-hepatocellular-carcinoma-patients-with-barcelona-clinic-liver-cancer-b-or-earlier-stage-a-systematic-review-and-meta-analysis
#20
Yun-Chen Li, Lin Zhao, Jiang-Ping Wu, Chen-Xu Qu, Qing-Kun Song, Rui-Bin Wang
BACKGROUND AIMS: To investigate the clinical benefits of cytokine-induced killer (CIK) cell infusions on hepatocellular carcinoma (HCC) patients, combined with other conventional treatments. METHODS: This was a systematic review and meta-analysis conducted among phase II and III randomized control trials worldwide. Review manager 5.2 version was used to pool the effect size across studies. Sensitivity analyses and risk of bias were estimated among included studies...
October 13, 2016: Cytotherapy
keyword
keyword
86070
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"